This is the company's language in the last PR. It doesn't say they are exploring strategic options. Its says they are reviewing viable options to pick the most favorable...that progress has been made and they expect to provide guidance in the near future. That's why I think some of the comments about management have been premature. At least let us see what they are working on. Maybe we'll no longer be a "binary" company. Maybe we'll consolidate with other bryostatin interested parties. Who knows and I have no idea how the market will react to whatever they come up with. I just think a dollar is the bottom here if not the 1.10 we've already seen. JMHO
Neurotrope continues to review several viable strategic alternatives. “We are continuing our efforts to identify the most favorable strategic alternative for the Company,” stated Charles S. Ryan, Neurotrope’s Chief Executive Officer. “The Committee has been working tirelessly in an effort to increase shareholder value. We are pleased with the progress that has been made and expect to provide additional guidance in the near future.”
News 
Market Data 
Discover 
